Vicore Pharma Holding AB Annual Shareholders Meeting Transcript
Welcome to this Vicore Pharma AGM presentation. Vicore Pharma is a rare disease company with focus on patients with fibrotic lung disease. Our primary indication is IPF, where C21, our first-in-class oral angiotensin type 2 receptor agonist is in Phase II for treatment of IPF. We started the study by the end of last year, and we expect to have top-line data by the end of next year. And we have European and US orphan drug designation as the IP for this indication.
We very recently announced an agreement with Alex Therapeutics to develop a prescription digital therapy, and that is to help patients in their anxiety and depression associated with IPF. And there, we have a clinical trial planned in 2022.
A separate program is dedicated to IPF cough, the VP-02 program, where we have inhaled thalidomide for the treatment of this severe and debilitating cough. We know that tablets work, but the severe side effect profile have prevented the use of thalidomide in this indication. So what we are doing is formulating this drug into
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
